CRISPR/Cas9 Treatment Can Improve Nerve Functioning in Mouse Model of CMT1A, Study Suggests
CRISPR/Cas9 Treatment Can Improve Nerve Functioning in Mouse Model of CMT1A, Study Suggests
Continue Reading
CRISPR/Cas9 Treatment Can Improve Nerve Functioning in Mouse Model of CMT1A, Study Suggests
Continue Reading2019.08.30_PXT3003_US_FDA_EN
Continue ReadingNantes, France – May 15th, 2019 InFlectis BioScience SAS, a drug discovery company committed to the development of innovative therapeutics […]
Continue ReadingThis brings us inline with the European CMT Federation of which we are a founding member organisation. It also prevents […]
Continue ReadingImplanting stem-derived Schwann-like cells into mice with Charcot-Marie-Tooth type 1A improved neuron function, leading to better motor activity and nerve […]
Continue ReadingAwareness Month has gone extremely well, kicking off with our trustee, Paul Fleming being on Sky News Sunrise on 1st […]
Continue ReadingMore than 200 delegates from around the world attended the conference held on 19th and 20th April in Fitzwilliam College, […]
Continue ReadingNantes, France – May 22th, 2018. InFlectis BioScience SAS, a drug discovery company committed to the development of innovative therapeutics […]
Continue ReadingResearchers have found that disease progression in Charcot-Marie-Tooth type 1A (CMT1A) patients reaches a critical point at age 50, after which […]
Continue ReadingROSE Brewis was an adult before she discovered she had progressive muscle-wasting disease CMT which affects thousands in the UK. […]
Continue ReadingLast Updated: Tuesday 1st October, 2019